Several lines of evidence have suggested that stemness and acquired resistance to targeted inhibitors or chemotherapeutics are mechanistically linked. Here we observed high cell surface and total levels of nerve growth factor receptor/CD271, a marker of melanoma-initiating cells, in sub-populations of chemoresistant cell lines. CD271 expression was increased in drug-sensitive cells but not resistant cells in response to DNA-damaging chemotherapeutics etoposide, fotemustine and cisplatin. Comparative analysis of melanoma cells engineered to stably express CD271 or a targeting short hairpin RNA by expression profiling provided numerous genes regulated in a CD271-dependent manner. In-depth analysis of CD271-responsive genes uncovered the association of CD271 with regulation of DNA repair components. In addition, gene set enrichment analysis revealed enrichment of CD271-responsive genes in drug-resistant cells, among them DNA repair components. Moreover, our comparative screen identified the fibroblast growth factor 13 (FGF13) as a target of CD271, highly expressed in chemoresistant cells. Further we show that levels of CD271 determine drug response. Knock-down of CD271 in fotemustine-resistant cells decreased expression of FGF13 and at least partly restored sensitivity to fotemustine. Together, we demonstrate that expression of CD271 is responsible for genes associated with DNA repair and drug response. Further, we identified 110 CD271-responsive genes predominantly expressed in melanoma metastases, among them were NEK2, TOP2A and RAD51AP1 as potential drivers of melanoma metastasis. In addition, we provide mechanistic insight in the regulation of CD271 in response to drugs. We found that CD271 is potentially regulated by p53 and in turn is needed for a proper p53-dependent response to DNA-damaging drugs. In summary, we provide for the first time insight in a CD271-associated signaling network connecting CD271 with DNA repair, drug response and metastasis.
INTRODUCTION
Despite recent progress in treatment options, malignant melanoma metastasized to liver, lung or brain remains to be a non-curable disease. Overall, the therapy of stage IV melanoma by chemotherapeutics and targeted therapies results in median progression-free survival of approximately 1.5-7 months and a 5-year survival period is observed for 10% of patients only. The major obstacle to long-term patient survival is resistance acquired under therapy. Although BRAF V600E mutated melanomas, which represent 40-60% of this tumor entity, are effectively targetable with the BRAF inhibitor vemurafenib, 1 relapse occurs as early as within approximately 5 months. 2 Resistant tumors exhibit upregulation of receptor tyrosine kinase receptors PDGFRB 3 or EGFR, 4 signaling mediators such as CRAF or NRAS, as well as mutations in MEK1, MEK2 and NRAS resulting in the stimulation of the RAS/RAF/mitogen-activated protein kinase pathway (reviewed in Spagnolo et al. 2 ). A recent publication suggested that resistance to vemurafenib was also dependent on the levels of nerve growth factor receptor (NGFR, CD271) and of drug-induced nuclear factor κB (NFκB) signaling. 5, 6 For therapy of melanomas lacking BRAF or other targetable mutations, the chemotherapeutics paclitaxel, cisplatin and dacarbacine are in clinical use, either administered in combination or as monotherapy. 7 Dacarbazine, its prodrug temozolomide, as well as fotemustine are favorably used to treat brain metastases because these inhibitors are capable of passing the blood-brain barrier. 8, 9 Clinical trials combining these drugs with immunological or targeted therapies are ongoing. 10, 11 It is well known that intrinsic resistance to chemotherapeutics involves the expression of active membrane transporters, [12] [13] [14] anti-apoptotic genes, 15, 16 genes associated with stemness 17, 18 and epigenetic modulators. 17 The increased DNA repair capacity of melanoma cells 18 provides an additional mechanism conferring intrinsic resistance to targeted drugs and chemotherapeutics. Although chemotherapy of melanoma cells leads to acquired resistance, DNA-damaging agents induce upregulation of DNA damage-binding protein 2 and xeroderma pigmentosum genes. 19 It has been shown that acquired resistance of melanoma and glioblastoma to fotemustine is directly linked to high expression of the de-alkylating enzymes. 20 Thus, acquired increase of the DNA repair capacity is likely to be a major mechanism of melanoma cells in evading chemotherapeutic interventions (reviewed in Soengas and Lowe 21 ). In view of the complexities of resistance mechanisms in chemoresistant melanoma, it is desirable to better understand the interplay of the determining factors and potential ways of their regulation. Therefore, we set out to explore new factors and regulatory mechanisms of therapy resistance by profiling chemoresistant BRAF wild-type melanoma cells. In addition, we analyzed the consequence of drug-induced changes in gene expression in non-resistant cells. 
RESULTS

Steady
. 22 By comparative analysis of profiling data, we identified subsets of genes whose elevated expression was either common or unique to the chemoresistant cells ( Figure 1a and Supplementary Tables S1A and B). MeWo
Cis cells were exceptional in that there were no marked expression alterations compared with MeWo Par cells. Among the strongly (fold change, FC ⩾ 2, P ⩽ 0.05) upregulated factors within the subset of 39 genes common to MeWo Fote and MeWo Vind cells, CD271 (NGFR) attracted our attention because of its propensity to mediate vemurafenib resistance 7 and stemness in melanoma 23 ( Figure 1a) . We verified the elevated transcription of CD271 by quantitative PCR (qPCR) and upregulation at the protein level by immunoblotting ( Figure 1b ). In addition, we quantified cell surface localization of CD271 by flow cytometry (Figure 1c ). On average, we found enrichment of CD271-expressing cells by a factor of 2. A CD271-associated gene signature uncovers a regulatory linkage with DNA repair Drug resistance is associated with numerous alterations of gene expression, 24 hence we asked if CD271 can modulate drug response by impacting on the transcriptome. To identify CD271-responsive transcriptional targets, we performed expression profiling of patient-derived melanoma cells T20/02 and the A375 cell line, both engineered to stably express CD271. Cell lines transfected with the CD271/green fluorescent protein (GFP) transgene showed increased endogenous and ectopic CD271 protein levels and increased cell surface localization (Supplementary Figure S2A) . Genome-wide expression profiling revealed 5233 and 736 differentially regulated genes (P ⩽ 0.05) in A375
NGFR/CD271 cells and T20/02 NGFR/CD271 cells, respectively (Supplementary Figures S2B and C) . Of those, 235 genes were upregulated in the two cell lines by CD271 (Figure 2a , Supplementary Table S3 ). In addition, we contrasted the expression data set of T20/02 NGFR/CD271 cells with those obtained after silencing endogenous CD271 in the same cell strain. 23 This comparison identified 577 genes modulated in conjunction with the deregulation of CD271 (Figure 2a ). Among those were 340 genes transcriptionally stimulated (⩾1.5-fold) following overexpression of CD271 (P ⩽ 0.05) and downregulated (⩽0.5-fold) by CD271 knock-down (P ⩽ 0.05), (Supplementary Table S4 ). In all, 237 genes followed a converse regulation, that is, were repressed by forced CD271 expression (Supplementary Figure S2D , Supplementary Table S5 ). For a deeper exploration of profiling data, we performed DAVID analysis 25, 26 of gene subsets and gene set enrichment analysis (GSEA) 27 of the entire data sets.
DAVID analysis of CD271-induced genes uncovered three clusters associated with gene functions in cell cycle (enrichment score (ES) = 1.58), DNA repair (ES = 1.34) and cell motility (ES = 1.28) (Figure 2a , right panel and Supplementary Figure S3A ). To further investigate the association between CD271-responsive genes and DNA repair, we performed GSEA, particularly considering a DNA repair gene signature deposited in Broad Institute's molecular signature database (MSigDB, http://software.broadinstitute.org/ gsea/msigdb/index.jsp). Indeed, GSEA revealed enrichment of genes involved in DNA repair (nominal enrichment score = 1.76) in CD271-overexpressing cells (T20/02 NGFR/CD271 ) and conversely regulated in CD271 knock-down cells (T20/02 k.d. ) (Figure 2b ). We confirmed the differential, CD271-dependent expression of RAD21, RAD51 (homologs of S. pombe and S. cervisiae, respectively), RAD51-associated protein 1 (RAD51AP1) genes, responsible for double-strand break repair, and of DNA damage-binding protein 2 and xeroderma pigmentosum genes involved in nucleotide excision repair (Wiese et al. 28 and reviewed in Sancar et al. 29 ) (Figure 2c ). In A375 NGFR/CD271 cells, RAD21, RAD51AP1 and other repair genes including MSH6 (homolog of Escherichia coli MutS) were equally upregulated in a CD271-dependent manner (Figure 2d and Supplementary Figure S3C ). To further prove the relationship between CD271 and increased expression of repair genes, we sorted three different patient-derived melanoma cell strains for high endogenous and low CD271 expression by fluorescence-assisted cell sorting. The expression pattern of the repair genes RAD21, RAD51, RAD51AP1 and MSH6 was correlated with that of CD271 in positively and negatively sorted cells (Figure 2e and Supplementary Figure S2E Figure S4A) . Genes of this subset followed a CD271-dependent regulation as validated in engineered cells (Supplementary Figure S4A , lower panels).
In addition, GSEA led to identification of a CD271-responsive gene signature in MeWo Fote and MeWo Vind cells (Figure 3b) , comprising important components of the DNA damage repair machinery such as PRKDC (DNA-dependent protein kinase catalytic subunit) and RAD51 and the cisplatin resistance associated gene encoding fibroblast growth factor 13 (FGF13). 30 We confirmed high expression of FGF13 CD271 in DNA-repair and drug response T Redmer et al cells ( Figure 4a ). Next, we assessed the susceptibility of CD271 knock-down cells to fotemustine. In MeWo Fote-shCD271 cells (clones shCD271_5-2 and shCD271_5-1), the susceptibility to fotemustine was partially restored as indicated by reduced viability of clone 5-2 at 100 μg/ml (76.9 ± 2.6% vs 109.9 ± 10.1%) and clone 5-1 at 300 μg/ml (47.5 ± 11.5% vs 78.6 ± 7.1%), as well as by enhanced apoptosis following 48-h treatment (Figure 4b ). In addition, we explored the response of clone 5-1 to cisplatin, vindesine and etoposide and observed that none of these showed a comparable response as compared with fotemustine (Supplementary Figure S5B) . Moreover, we performed a stable knock-down of CD271 in MeWo Vind cells, by two independent short hairpin RNAs (shRNAs; sh#3, sh#4) yielding in a robust downregulation of CD271 (Figure 4c CD271-responsive genes confer a metastatic phenotype on melanoma cells As selective pressure occurring upon drug-based therapies can lead to changes in expression levels of genes favoring metastasis and relapse, 31, 32 we asked whether expression of CD271 and its responsive genes may be involved in mediating a migratory/ metastatic phenotype. We took advantage of a life cell imaging system based wound-healing assay, which allowed us to monitor migration of A375 NGFR/CD271 and MeWo Par-NGFR/CD271 and control cells (A375 GFP , MeWo Par-GFP ) within 2 days. We observed that overexpression of CD271 in A375 and MeWo cells specifically increased the migratory phenotype and accelerated wound closure in both cellular systems (Figure 5a Figure S7A ). The CD271-responsive genes RAD51AP1 and the known resistance mediators NIMA-related kinase 2 (NEK2) 33 and Hyaluronan-mediated motility receptor (HMMR), 34 as well as topoisomerase II were highly expressed in MeWo Fote cells (Figure 5d , left panel and data not shown). The CD271-dependent upregulation of NEK2, HMMR and TOP2A observed by GSEA was validated (Figure 5d , center and right panel and Figure 2d ). To further assess whether expression of CD271-responsive genes may not only promote chemoresistance but also metastasis formation, we took advantage of publicly available expression profiling data of primary (n = 31) and In (d, g) , scales indicate relative expression levels ± s.d. of independent triplicates, *P ⩽ 0.05; **P ⩽ 0.01; ***P ⩽ 0.001. CD271 in DNA-repair and drug response T Redmer et al metastatic melanoma (n = 52). 35 Exploration of the set of upregulated genes (n = 1054, 42-fold, P ⩽ 0.05) revealed the presence of 110 CD271-responsive genes, upregulated in melanoma metastases (Figure 5e and Supplementary Table S7) .
Among them, we found NEK2, RAD51AP1 and LYPD1 (LY6/PLAUR domain containing 1), a neuronal transmembrane protein potentially associated with brain metastases. 36 Statistical analysis revealed that expression of the CD271-responsive genes NEK2 (P = 1.56E-06), RAD51AP1 (P = 2.67E-04), HMMR (P = 5.47E-07) and TOP2A (P = 1.56E-06) but not FGF13 (P = 0.3122) significantly discriminated primary tumors and melanoma metastases (Figure 5f and Supplementary Figures S7B Figure S7D) . 37 Keratin 17 was found inversely correlated with expression of CD271-responsive genes in melanoma metastases (Figure 5f ), upregulated upon CD271 knock-down (data not shown). The role of CD271 as mediator of melanoma metastasis is further underpinned by the inverse regulation of the known suppressor of melanoma metastasis KISS1 38 and DMBT1 (deleted in brain tumors 1). DMBT1 expression is frequently lost in lung cancer 39 and glioblastoma. 40 We observed a strong upregulation of both genes upon knock-down of CD271 in MeWo derivatives and T20/02 cells ( Supplementary Figures S6D and E) , suggesting that CD271 expression leads to repression of both metastasis inhibitors, facilitating melanoma metastasis.
As we identified mediators of melanoma metastasis among CD271-responsive genes, we next asked whether these genes can be induced in MeWo Par cells by fotemustine treatment. We observed increased expression of NEK2 and RAD51AP1 (Supplementary Figure S7E , left panel) as well as strong increased levels of the ligands of CD271, nerve growth factor (NGF, 13.5-fold) and neurotrophin 4 (~3.5-fold) (Figure 5g ) following fotemustine treatment for 24 h. Brain-derived neurotrophic factor was only marginally increased, melanoma antigen recognized by T cells 1 showed inverse correlation with CD271 and neurotrophins. In conclusion, the enhanced expression of neurotrophins like NGF upon drug treatment and in drug-resistant cells (MeWo Fote ) (Supplementary Figure S7E , right panel) suggests that the genetic programs governing drug resistance and metastasis may overlap at least partially.
CD271 is induced in a p53-dependent manner
To assess the mechanisms regulating the drug-mediated induction of CD271, we explored signaling processes potentially induced on drug treatment of MeWo Par cells. Pathway components included stabilized p53 (p-p53 S15 ), p21 CIP (CDKN1A), mitogen-activated protein kinase (extracellular signal-regulated kinases 1 and 2 (ERK1/2), p38 kinase), AKT signaling as well as checkpoint-kinase 1 (CHK1), a direct target of ataxia telangiectasia mutated and ataxia telangiectasia and RAD3-related signaling. The latter is the DNA damage sensor pathway and marks sites of DNA damage via formation of γH2AX a crucial step initiating DNA repair. 29 We also determined phosphorylation of IκBα and the nuclear localization of NFκB/p65, as activation of NFκB signaling was earlier recognized as a proposed mechanism of CD271 regulation. 7 We observed a strong activation of mitogen-activated protein kinase signaling (p-ERK1/2) and the p53-signaling pathway following treatment with cisplatin (Cis), etoposide (Eto) or temozolomide, as well as a moderate activation of p38 kinase and CHK1 (Figure 6a) , however, we did not detect activation of canonical NFκB signaling (Figure 6a and Supplementary Figure S8A) . In contrast to MeWo Par cells, p53 was not stabilized in chemoresistant MeWo Eto and MeWo Cis cells upon drug treatment (Figure 6b) . Moreover, known p53 targets 41 and CD271 were co-regulated in etoposide-treated MeWo Par but not in MeWo
Eto cells (Figure 6c ), supporting the conclusion that the p53 pathway is impaired in resistant cells. We observed a lower induction of p53 targets upon treatment with cisplatin in MeWo Par cells as compared with etoposide and also observed a weak regulation of targets in MeWo Cis cells (Supplementary Figure S8B) . To further assess the connection between p53 and CD271, we investigated the response of the p53 pathway in a patient-derived cell strain following stable knock-down of CD271 and dosedependent treatment with etoposide. Etoposide treatment increased levels of γH2AX, p-p53 S15 and p21 CIP in control cells but not in CD271 knock-down cells (Figure 6d ). The levels of p53 itself, of p53 targets, as well as of the DNA damage sensors PRKDC, Nijmegen breakage syndrome 1 and ataxia telangiectasia mutated were downregulated in CD271 knock-down cells. Expression of ataxia telangiectasia and RAD3-related was not affected (Figure 6e and Supplementary Figure S9A ). In line with downregulation of DNA repair genes, knock-down cells showed increased DNA damage (Supplementary Figure S9A , center and right panels). These data suggest that endogenous levels of CD271 are required for proper drug response. We observed comparable CD271-dependent regulations of p53 targets and sensors of DNA damage repair in MeWo Fote and MeWo Vind cells upon knock-down of CD271 albeit with lower significance (Supplementary Figures S9A  and B) .
The co-regulation of p53 and CD271 in drug-exposed MeWo 
DISCUSSION
Stem cell-like properties are considered as a major cause for rendering cancer cells intrinsically resistant to therapeutics. 42, 43 NGFR (tumor necrosis factor superfamily member 16 or CD271) has been used as a marker to enrich for tumor-initiating cells in melanoma. 44 Our own previous findings had indicated that CD271 not only regulates stem cell functions, for example, tumorigenicity and plasticity, but was also highly expressed in patient-derived cell cultures from melanoma metastases. 23 These results prompted the current investigation as to whether CD271 was involved in chemoresistance, particularly in wild-type BRAF melanomas not eligible for anti-BRAF kinase therapy. We show here that selection of MeWo cells for acquired resistance to chemotherapeutics triggering DNA damage via alkylation, cross-linking of DNA or topoisomerase inhibition was accompanied by high CD271 expression. High expression of CD271 was maintained in resistant cells, with exception of MeWo Cis cells, which may have developed a different mechanism to overcome cisplatin-induced DNA damage without the need for CD271. However, short-term exposure of drug-sensitive cells to chemotherapeutics induced CD271 expression already after 4 h, suggesting that CD271 upregulation and drug exposure were directly linked rather than due to selection of highly expressing cells present in a CD271 in DNA-repair and drug response T Redmer et al heterogeneous cell population. Moreover, silencing of CD271 partially re-sensitized resistant cells toward drug treatment and identified a link between enhanced CD271 expression and the regulation of FGF13, a known mediator of cisplatin resistance. 30 Upregulation of CD271 in response to drugs occurred in a p53-dependent manner. However, the relationship between CD271 and p53 appeared to be more complex and additional general mechanisms involved in stress response 45 may trigger CD271 expression. In drug-sensitive melanoma cells, in which intrinsically moderate CD271 expression was silenced by introduction of shRNA, the p53-dependent DNA repair system was impaired because of low expression or activation of p53 and of crucial proteins acting as DNA damage sensors PRKDC, Nijmegen breakage syndrome 1 and ataxia telangiectasia mutated. This suggested that a sufficient level of CD271 in turn is required for the proper response of cells to chemotherapeutic drugs. This conclusion is based on the results of gene expression profiling of cells in which CD271 was either silenced or enhanced by ectopic expression of a recombinant CD271 expression vector. CD271-related gene signatures comprised predominantly DNA repair genes, cell cycle progression genes and genes involved in metastasis. This may explain why DNA repair genes are expressed at a higher level in CD271-expressing chemoresistant melanoma cells in the absence of p53 expression levels exceeding those in drug-sensitive cells. However, a CD271-independent upregulation of the DNA repair machinery cannot be excluded at this stage. Moreover, although our survey points out a role of CD271 in drug resistance, we only observed a partial sensitization of MeWo Fote or MeWo Vind cells to certain drugs. In addition, overexpression of CD271 was unable to fully mimic the resistant phenotype of observed in any of the resistant cells lines. This suggests that additional mechanisms are present in chemoresistant melanoma cells and clonal heterogeneity supposedly lead to variabilities in drug response.
Besides DNA repair genes, ectopic CD271 expression impinged on target genes, which have previously been associated with melanoma relapse and metastasis. 18, 46 Our survey of potential CD271-associated genes in publicly available melanoma expression profiles recovered as many as 110 CD271-responsive genes predominantly expressed in metastases, among them the NEK2 gene (Never in mitosis gene A-related kinase 2), previously found associated with drug resistance in myeloma 33 and RAD51AP1 previously associated with metastasis of melanoma and breast cancer 18, 47 as well as TOP2A (topoisomerase II). Expression of TOP2A was associated with worse prognosis in melanoma.
48 NEK2 was also identified as a regulator of aldehyde dehydrogenase 1, a marker of cancer-initiating cells, 49 again linking stem cell function and drug resistance. A hypothetical model depicting the regulation of CD271 and downstream effects is shown in Figures 7a-d .
Metastasis to the brain is frequently observed in melanoma patients, therapeutically treated with drugs able to pass the blood-brain barrier, such as fotemustine, temozolomide or dacarbacine. Recent publications demonstrated that expression of CD271 is frequently observed in melanoma brain metastases. 50 These findings are in line with our observation defining a crucial role of CD271 in regulating metastasis gene expression and conferring chemoresistance. Moreover, CD271 expression was found in brain metastatic melanoma cells resistant to vemurafenib. 8 These observations underpin our finding that CD271-responsive genes were also predominantly expressed in a small set of matched melanoma brain metastases. Notably, NGF mediates melanoma cell migration and metastasis as reported previously. 51 High expression of metastasis-associated CD271-responsive genes NEK2, RAD51AP1, TOP2A and NGF in drug-resistant MeWo cells and their drug-dependent regulation, may have consequences for the priming of melanoma cells for metastasis. Although FGF13 shows no statistical significant discrimination between melanoma primary tumors and metastases, we observed that subsets of melanoma metastases show high expression of either FGF13 or LYPD1. The role of both genes are poorly understood in melanoma metastases, however, FGF13, which is a special type of FGFs, is not only associated with signaling processes but also has a role in microtubule stabilization and the regulation of neuronal polarization and migration. 52 Hence, FGF13 may present a new driver of melanoma metastasis.
In general, these findings lead to the provocative hypothesis that sustained expression of CD271 may activate a genetic program promoting simultaneously drug resistance and metastasis. CD271-expressing cells potentially start to metastasize earlier than CD271-negative cells. This is further underpinned by a very recent work 53 and our observation that melanoma cells with a high endogenous level or overexpression of CD271 showed increased migration into a scratch wound, suggesting CD271 as a determining factor in melanoma metastasis and a candidate factor determining drug response.
MATERIALS AND METHODS
Cell culture
All primary low passage melanoma cell strains, as well as their derivatives were cultured in Quantum 263 tumor growth medium (Q236, Capricorn Scientific, Marburg, Germany) supplemented with 1% penicillin/streptomycin (Invitrogen, Carlsbad, CA, USA). The patient tumor-derived cell strain T20/02 has been established from a lymph node metastasis. A375 cells (ATCC, Manassas, VA, USA) and MeWo cell lines were cultured in Leibovitz's L-15 medium (Invitrogen) supplemented with 10% fetal bovine serum, 1%, penicillin/streptomycin (Invitrogen), transferrin/fetuin, minimum essential medium-vitamins, insulin, glucose and sodium bicarbonate. Nextgeneration sequencing of T20/02 and MeWo cells revealed absence of mutations in BRAF or RAS (K/H/N), Supplementary Table S2A . Cells were cultured in 5% CO 2 , 37°C and routinely passaged at 80% confluence. Medium was changed every 3 days. Stably shRNA or control transfected fotemustine-resistant cells were selected for puromycine resistance (10 μg/ ml) and sub-cloned by limited dilution assays, which yielded in clones 5-1 and 5-2. Vindesine resistant cells were transfected with shRNA or control plasmids, selected for generation of cell pools.
Drug treatment assays
Drug treatments were performed for at least 48 h in six-well plates (2.5 × 10 5 cells seeded) for RNA/protein extraction or 96-well plates (2500 cells per well seeded) for viability assays. Stock solutions of etoposide (10 mM, dimethylsulfoxide), cisplatin (1670 mM, sodium chloride, 0.9%), temozolomide (10 mM, dimethylsulfoxide) and nutlin-3a (10 mM, dimethylsulfoxide), (all from Sigma-Aldrich, Munich, Germany) and fotemustine (50 mg/ml, ethanol, 80%) were used. Fotemustine was received either directly from the hospital and administered to cells at day of preparation, or received from company (Sigma-Aldrich). Viability was determined by MTT assay using 50 μl of MTT solution (5 mg/ml) added 48 h after drug treatment. Concentration of dimethylsulfoxide-solubilized formazan was detected at 570 nm after 1 h of incubation.
Flow cytometry/fluorescence-assisted cell sorting Fluorescence-assisted cell sorting and flow cytometry were performed as reported previously. 23 Data analysis was done with FlowJo software (http://www.flowjo.com/).
Immunoblot
Total cell lysates were prepared in sodium dodecyl sulfate lysis buffer (1% sodium dodecyl sulfate, 10 mM Tris-HCl, 2 mM EDTA). In all, 10-25 μg of whole-cell lysates were separated on 12% sodium dodecyl sulfatepolyacrylamide gel electrophoresis gels and transferred on a nitrocellulose membrane by using the iBlot Dry Blotting System (Invitrogen). Membranes were blocked with Odyssey Blocking Buffer/phosphate-buffered salineTween (0.1%), (1:1, LI-COR Biosciences, Lincoln, NE, USA) for 1 h. Incubation with primary antibodies (p75NTR clone D4B3XP recognizing the total CD271, p-ERK1/2, ERK1/2, p-AKT(S473), AKT, γH2AX, p21CIP, p-p53(S15), p-IĸBα, p-p38, p-Chk1 and β-tubulin, clone 9F3; all 1:1000; from Cell Signaling Technology, New England Biolabs GmbH, Frankfurt am Main, Germany) was done overnight at 4°C. Incubation with secondary antibodies donkey anti-rabbit immunoglobulin G or donkey anti-mouse both (diluted 1:10 000; LI-COR Biosciences) was done for 1 h at room temperature. Signals were detected with the Odyssey Infrared Imaging System (LI-COR Biosciences).
RNA isolation and quantitative reverse transcriptase-PCR
RNA isolation was performed as reported previously. 23 Primers were designed using the PrimerQuest Tool (http://eu.idtdna.com/ primerquest/ home/index) for 55-60°C annealing temperatures and product size of 100-250 bp (Supplementary Table S8 ).
Immunofluorescence IF was performed as reported previously. 23 Incubation with primary antibodies CD271-PE (Miltenyi, Bergisch Gladbach, Germany, clone ME20.4-1.H4, mouse IgG1, 1:100), γH2AX (1:250, Cell Signaling Technology), NFκB/ p65 and p53 (Cell Signaling Technology, 1:100) or TRITC-labeled phalloidin (1:1000, Sigma-Aldrich) diluted in blocking buffer was done overnight at 4°C
. Second day, cells were washed 3x with phosphate-buffered saline, and incubated with secondary antibodies AlexaFluor488/555 or 594 (1:500) recognizing either rabbit or mouse-produced antibodies and 4′,6-diamidin-2-phenylindol (Sigma-Aldrich, 1:500) for 1 h at room temperature. Washed cells were covered with 500 μl phosphate-buffered saline and used for microscopy. IF pictures were recorded with Zeiss Axiovert40CFL with accompanied Illuminator HPX120C and software AxioVision Rel. 4.8 (all Carl Zeiss AG, Oberkochen, Germany). ), as well as fotemustine or vindesine resistant cells (MeWo Fote ; MeWo Vind ) was performed with the scratch wound cell migration assay (Essen Bioscience Ltd, Welwyn Garden City, Hertfordshire, UK) following the manufacturer's instructions. Briefly, 30 000 cells of each cell line were seeded 24 h before, yielding in a dense cell layer. Reproducibly wounds were scratched with the Wound Maker, a block with 96 pins. After wounding, the 96-well plate was placed into the Incucyte ZOOM life-cell imaging system (Essen Bioscience Ltd.). Cell migration was monitored every 2 h for 2 days, using a × 10 magnification. Serial pictures were stacked for movie preparation using the ImageJ software (https://imagej.nih.gov/ij/). Statistical analysis was performed by using a two-tailed, paired t-test.
Generation of stable cell lines
Knock-down of CD271 was performed as reported previously. 23 For overexpression, melanoma cells were stably transfected with a plasmid expressing GFP-tagged human NGFR (RG207966, OriGene, Rockville, MD, USA) and selected with G418 (100-300 μg/ml, PAA). Stable GFP-expressing control cell lines were established by viral transduction with pLenti-PGK-GFP (Addgene, Cambridge, MA, USA). Briefly, 5 × 10 6 293LTV (BIOCAT GmbH, Heidelberg, Germany) were transfected with 4.5 μg pLenti-PGK-GFP plasmid and 4.5 μg packaging plasmid (pLenti Combo Mix I, HIV Lentiviral Packaging Plasmid Mix, BIOCAT) using calcium chloride precipitation. Virus containing supernatant was collected 48 h after transfection and concentrated (~50-fold) using PEG-it solution (SBI, Palo Alto, CA, USA).
Gene expression profiling
Whole-genome expression profiling of chemoresistant and sensitive melanoma cells (MeWo, GSE78898) or cells of a patient-derived cell strain (T20/02) stably transfected either with a CD271-targeting (T20/02 k.d.
) or a control shRNA (GSE52456) plasmid, as well as T20/02 and A375 cells stably expressing either NGFR/CD271 or GFP (GSE78155) was performed with three biological replicates. Gene expression of parental (n = 1) and chemoresistant derivatives (Eto, Fote n = 3; Vind, Cis n = 2) was measured on two Illumina BeadChips (HumanHT-12V4, Illumina Inc., San Diego, CA, USA). After summarization via BeadStudio, data on each chip was quantile normalized (R package preprocessCore) and filtered (detection Po0.01 for at least one sample). After combination of chips by quantile normalization and batch correction (R package sva), significance thresholds for differential regulation were set to mean FC ⩾ 2 and adjusted P-value o0.05 (R package limma). Plots and heat maps were generated using R packages ggplot2 and heatmap.3 with spearman's rank correlation as similarity measure and complete linkage.
Gene set enrichment analysis GSEA was performed with appropriate software (GSEA version 2.2.2, Cambridge, MA, USA), as well as signatures specific for DNA repair, melanoma relapse and melanoma metastasis were received from the latest version of the Molecular Signatures Database v5.1 (MSigDB, GSEA) of the Broad Institute (http://software.broadinstitute.org/gsea/ downloads.jsp). The CD271-responsive gene signature represents a consensus (n = 516 genes) of genes upregulated in A375 NGFR/CD271 and/or T20/02 NGFR/CD271 cells. DAVID analysis was used to derive a sub-signature (n = 187 genes) from the consensus signature comprising genes associated with DNA repair and cell cycle processes.
Meta-analysis
Exploration for presence of CD271-responsive genes, publicly available data were used comprising primary melanoma with melanoma metastases of different organs (GSE8401) or extracranial with brain metastases (GSE50496). From the latter study, only matched pairs of extracranial and brain metastases were taken into consideration for analysis. Data were downloaded from GEO (http://www.ncbi.nlm.nih.gov/geo). Statistical analysis of CD271-responsive genes differentially expressed among melanoma metastases and primary melanoma was done in R using a modified version of the linear model function (lm).
Panel-based sequencing and copy number variation (CNV) 
